Conflict of interests

Unless otherwise stated, all authors have no conflicts of interest. D.A. Hesselink reports receiving lecture and consulting fees from Astellas Pharma, Chiesi Pharma, Medincell, Novartis Pharma, and Vifor Pharma and receiving grant support from Astellas Pharma, Bristol-Myers Squibb, and Chiesi Pharma [paid to his institution], without employment or stock ownership at any of these companies, nor does he have patents or patent applications.

Ethical approval

This study including human participants was performed in line with the ethical principles of the Declaration of Helsinki and its later amendments. Approval was granted by the Ethics Committee of Erasmus Medical Center (Ethics approval number: 2018–035).

Informed consent to participate and publish

Informed consent regarding participating and publishing data was obtained from all individuals included in this study.